HUP9901455A2 - Szomatosztatin peptidek - Google Patents

Szomatosztatin peptidek

Info

Publication number
HUP9901455A2
HUP9901455A2 HU9901455A HUP9901455A HUP9901455A2 HU P9901455 A2 HUP9901455 A2 HU P9901455A2 HU 9901455 A HU9901455 A HU 9901455A HU P9901455 A HUP9901455 A HU P9901455A HU P9901455 A2 HUP9901455 A2 HU P9901455A2
Authority
HU
Hungary
Prior art keywords
residue
ala
amino acid
statin
formula
Prior art date
Application number
HU9901455A
Other languages
English (en)
Inventor
Rainer Albert
Wilfried Bauer
Christian Bruns
Nagarajan Chandramouli
Ian Lewis
Gisbert Weckbecker
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26307298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9901455(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9513224.7A external-priority patent/GB9513224D0/en
Priority claimed from GBGB9600429.6A external-priority patent/GB9600429D0/en
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP9901455A2 publication Critical patent/HUP9901455A2/hu
Publication of HUP9901455A3 publication Critical patent/HUP9901455A3/hu
Publication of HU228984B1 publication Critical patent/HU228984B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

A találmány tárgya az (I) általánős képletű szekvenciát tartalmazószőmatősztatin analógők - a képletben X1 jelentése helyettesített Thr,Ser, Tyr, Glű vagy Cys maradék, és X2 jelentése a-aminősav, amely aCa-őldalláncőn arőmás maradékőt hőrdőz, vagy egy, a Dab, a Dpr, a Dpm,a His, a (Bzl)HyPrő, a tienil-Ala, a ciklőhexil-Ala és a terc-bűtil-Ala közül választőtt aminősavegység, és az említett szekvencia Lysmaradéka a természetes szőmatősztatin-14 Lys9 maradékának felel meg -szabad főrmában, só vagy egy detektálható fémmel alkőtőtt kőmplexfőrmájában értékes farmakőlógiai tűlajdőnságőkkal rendelkeznek. ŕ
HU9901455A 1995-06-29 1996-06-28 Cyclic somatostatin hexapeptides HU228984B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9513224.7A GB9513224D0 (en) 1995-06-29 1995-06-29 Organic compounds
GBGB9600429.6A GB9600429D0 (en) 1996-01-10 1996-01-10 Organic compounds
PCT/EP1996/002840 WO1997001579A2 (en) 1995-06-29 1996-06-28 Somatostatin peptides

Publications (3)

Publication Number Publication Date
HUP9901455A2 true HUP9901455A2 (hu) 1999-09-28
HUP9901455A3 HUP9901455A3 (en) 2000-11-28
HU228984B1 HU228984B1 (en) 2013-07-29

Family

ID=26307298

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901455A HU228984B1 (en) 1995-06-29 1996-06-28 Cyclic somatostatin hexapeptides

Country Status (24)

Country Link
US (1) US6225284B1 (hu)
EP (1) EP0835263B9 (hu)
JP (2) JP3445796B2 (hu)
KR (1) KR100454664B1 (hu)
CN (1) CN1156492C (hu)
AT (1) ATE210152T1 (hu)
AU (1) AU714447B2 (hu)
BR (1) BR9609335B8 (hu)
CA (1) CA2222524C (hu)
CZ (1) CZ297381B6 (hu)
DE (1) DE69617687T2 (hu)
DK (1) DK0835263T3 (hu)
ES (1) ES2169251T3 (hu)
HU (1) HU228984B1 (hu)
IL (1) IL122243A (hu)
MY (1) MY147327A (hu)
NO (1) NO317867B1 (hu)
NZ (1) NZ313147A (hu)
PL (1) PL184947B1 (hu)
PT (1) PT835263E (hu)
SK (1) SK284087B6 (hu)
TR (1) TR199701718T1 (hu)
TW (1) TW491854B (hu)
WO (1) WO1997001579A2 (hu)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238340B1 (en) * 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
JPH10251296A (ja) * 1997-03-06 1998-09-22 American Cyanamid Co ソマトスタチン拮抗薬として有用なペプチド
AU8019798A (en) 1997-05-13 1998-12-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Method and compositions for treating hyperlipidemia and other conditions
WO1998051331A1 (en) 1997-05-13 1998-11-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Somatostatin and somatostatin agonists for decreasing body weight
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
SE9802080D0 (sv) * 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
EP1233776A4 (en) * 1999-11-29 2003-05-07 Smithkline Beecham Corp CYCLIC UROTENSIN II ANALOGS
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7906103B2 (en) 2000-03-08 2011-03-15 Gerhard Graupner Methods and compositions for targeted drug delivery
US7122172B1 (en) 2000-03-08 2006-10-17 Gerhart Graupner Methods and compositions for targeted drug delivery
CZ305160B6 (cs) 2001-06-08 2015-05-27 Ipsen Pharma S.A.S. Chimérické somatostatin-dopaminové analogy
US7189856B2 (en) * 2001-12-28 2007-03-13 Gideon Shapiro Non-peptide somatostatin receptor ligands
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
ATE494010T1 (de) * 2002-02-27 2011-01-15 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7122622B2 (en) 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
EP1358890A1 (en) 2002-05-03 2003-11-05 BioSynthema, Inc Benzothienyl analogue of somatostatine, selective for certain somatostatin receptors
PL213029B1 (pl) 2002-05-20 2012-12-31 Bristol Myers Squibb Co Podstawiona pochodna cykloalkilowa, zawierajaca ja kompozycja oraz ich zastosowanie
ES2350201T3 (es) 2002-05-20 2011-01-20 Bristol-Myers Squibb Company Sulfamidas heterocíclicas como inhibidores del virus de la hepatitis c.
ATE503764T1 (de) * 2002-05-20 2011-04-15 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
BR0316523A (pt) * 2002-11-25 2005-10-18 Attenuon Llc Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
GB0229020D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic compounds
SI1572615T1 (sl) * 2002-12-12 2010-06-30 Novartis Ag Postopek za sintezo peptidov ki vsebujejo hidroksi prolinsko substrukturo
GB0300095D0 (en) * 2003-01-03 2003-02-05 Novartis Ag Organic compounds
KR20070108953A (ko) 2003-04-22 2007-11-13 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 펩타이드 벡터
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
KR20060094083A (ko) 2003-09-22 2006-08-28 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스에 대해 활성인 마크로사이클릭펩타이드
EP1522311A1 (fr) 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
GB0326602D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DE602005025855D1 (de) 2004-01-21 2011-02-24 Boehringer Ingelheim Pharma Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
EP1717247A1 (en) * 2005-04-28 2006-11-02 Schering AG Cyclic peptides binding to the somatostatin receptor
WO2006114324A1 (en) * 2005-04-28 2006-11-02 Schering Ag Compounds comprising cyclized somatostatin receptor binding peptides
EP1941902A1 (en) * 2007-01-02 2008-07-09 Novartis AG Use of Somatostatin analogs in cluster headache
BRPI0813733A2 (pt) 2007-06-29 2019-11-05 Gilead Sciences Inc composto com atividade inibidora de hcv, sua composição farmacêutica e seu uso.
CA2691442C (en) * 2007-06-29 2014-01-21 Gilead Sciences, Inc. Antiviral compounds
RU2523416C2 (ru) 2007-11-28 2014-07-20 Новартис Аг Применение аналогов соматостатина при менингиоме
EP2067786A1 (en) 2007-12-07 2009-06-10 ITALFARMACO S.p.A. Novel non selective analogs of somatostatin
BRPI0818978B8 (pt) * 2007-12-03 2021-05-25 Italfarmaco Spa novos análogos não-seletivos da somatostatina
KR101642363B1 (ko) 2008-06-12 2016-07-25 입센 바이오이노베이션 리미티드 신경내분비계 질환의 억제
KR101731655B1 (ko) 2008-06-12 2017-05-11 입센 바이오이노베이션 리미티드 암 억제 방법
JP5721624B2 (ja) 2008-07-08 2015-05-20 ノバルティス アーゲー 内因性高インスリン血症性低血糖症の治療のためのパシレオチドの使用
EP2213307A1 (en) 2009-02-03 2010-08-04 Novartis AG Injectable depot formulations
EP2172189A1 (en) 2008-10-01 2010-04-07 Novartis AG Pharmaceutical Compositions
EP2168983A1 (fr) 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
AU2009335904A1 (en) * 2008-12-19 2011-08-04 Gilead Sciences, Inc. HCV NS3 protease inhibitors
EP2380596A1 (en) * 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptide derivatives and uses thereof
US20210317161A1 (en) 2014-12-19 2021-10-14 Auro Peptides Ltd A process for the preparation of pasireotide
CN106432429A (zh) * 2016-10-24 2017-02-22 合肥国肽生物科技有限公司 一种帕西瑞肽的合成方法
CN110678227B (zh) 2017-01-12 2023-03-21 雷迪奥梅迪克斯股份有限公司 使用与放射性同位素螯合的奥曲肽衍生物治疗过表达生长抑素受体的癌细胞
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863008A (en) * 1973-06-11 1975-01-28 American Home Prod Somatostatin as stimulant of luteinizing hormone secretion
NZ195303A (en) * 1979-10-31 1984-10-19 Merck & Co Inc Cyclic hexapeptide somatostatin analogues,and pharmaceutical compositions
US4292972A (en) * 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
US4505897A (en) * 1983-04-18 1985-03-19 The Administrators Of The Tulane Educational Fund Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
US4612366A (en) 1985-06-17 1986-09-16 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
CA2012115C (en) * 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
JP2882679B2 (ja) * 1989-04-26 1999-04-12 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 線状ソマトスタチン類似体
US5716596A (en) * 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
EP1099707A3 (en) 1993-06-23 2002-01-09 Diatide, Inc. Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses

Also Published As

Publication number Publication date
CZ419697A3 (cs) 1998-05-13
HU228984B1 (en) 2013-07-29
EP0835263B9 (en) 2002-07-24
AU6515096A (en) 1997-01-30
KR100454664B1 (ko) 2005-09-12
SK177097A3 (en) 1998-08-05
BR9609335B8 (pt) 2014-10-07
PL184947B1 (pl) 2003-01-31
CZ297381B6 (cs) 2006-11-15
CN1156492C (zh) 2004-07-07
MY147327A (en) 2012-11-30
CN1189166A (zh) 1998-07-29
JP3445796B2 (ja) 2003-09-08
ATE210152T1 (de) 2001-12-15
EP0835263A2 (en) 1998-04-15
IL122243A0 (en) 1998-04-05
BR9609335A (pt) 1999-05-25
DE69617687D1 (de) 2002-01-17
EP0835263B1 (en) 2001-12-05
TR199701718T1 (xx) 1998-05-21
NO976064L (no) 1998-02-16
CA2222524C (en) 2010-01-26
BR9609335B1 (pt) 2009-08-11
PL323943A1 (en) 1998-04-27
KR19990028480A (ko) 1999-04-15
ES2169251T3 (es) 2002-07-01
JP2003104998A (ja) 2003-04-09
US6225284B1 (en) 2001-05-01
JPH11506108A (ja) 1999-06-02
HUP9901455A3 (en) 2000-11-28
PT835263E (pt) 2002-04-29
CA2222524A1 (en) 1997-01-16
IL122243A (en) 2005-09-25
DK0835263T3 (da) 2002-04-02
NZ313147A (en) 1999-11-29
DE69617687T2 (de) 2002-08-22
TW491854B (en) 2002-06-21
SK284087B6 (sk) 2004-09-08
NO976064D0 (no) 1997-12-23
WO1997001579A3 (en) 1997-02-27
WO1997001579A2 (en) 1997-01-16
NO317867B1 (no) 2004-12-27
AU714447B2 (en) 2000-01-06

Similar Documents

Publication Publication Date Title
HUP9901455A2 (hu) Szomatosztatin peptidek
ES2063350T3 (es) Nuevas proteinas con efecto inhibidor del tnf y su produccion.
Low et al. The chemistry and biology of thymosin. II. Amino acid sequence analysis of thymosin alpha1 and polypeptide beta1.
HUP9901718A2 (hu) Parathyroid hormon analógok
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
HUP9702307A2 (hu) Antigén kibocsátásra alkalmas készítmény
HUP0004639A2 (hu) Chlamydia fehérje, génszekvencia és ezek alkalmazása
NO981395D0 (no) Cykliske peptidanaloger av somatostatin
HUP0000432A2 (hu) Inzulin C-peptidek
ES2051647A1 (es) Procedimiento para la preparacion de calcitonina de salmon.
HUP0301396A2 (hu) Integrin inhibitor hatású peptid- és peptidutánzó konjugátumok, azokat tartalmazó implantátumok és alkalmazásuk
HUP0004605A1 (hu) Presenilinek és a béta-amiloid peptid vagy prekurzora közötti kölcsönhatás gátlására képes peptidek
DK0946591T3 (da) Klonede glucagon-lignende peptid-2 receptorer
ATE393224T1 (de) Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse
HUP0000836A2 (hu) Kollagén II-re specifikus T-sejt epitópot tartalmazó peptidek
ECSP961798A (es) Peptidos de somatostatina
KR850002285A (ko) 면역 인터페론의 제조방법
Zhao et al. A novel approach for iodolabelling synthetic peptides
Van den Heever et al. Synthesis and binding of peptide T and aminoacyl derivatives to CD4+ lymphocytes
YOSHIDA et al. The Effect of Nighttime Naps on the Subsequent Arousal Levels
ES2051152B1 (es) Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados.